CCRE Researchers
Professor Henry Krum
Director, CCRE - Therapeutics
Professor Henry Krum is a well recognised figure in cardiovascular clinical pharmacology and therapeutics, attested to by his extensive professional activities in this area. Prof Krum is also a physician at the Alfred Hospital in Melbourne and heads Clinical Pharmacology at Monash University and the Alfred Hospital. His interests lie with heart failure and hypertension, and his work spans the fields of basic, clinical and applied sciences.
Prof Krum has been a member of many International Steering and Executive Committees for major clinical trials in the area of cardio-vascular pharmacotherapy. He currently leads a number of multicentre investigator-initiated trials testing cardiovascular therapeutic strategies.
A/Prof Christopher Reid
Associate Director, CCRE - Therapeutics
A/Prof Reid is an epidemiologist with a background in exercise physiology. He has extensive experience in management of large-scale clinical studies and data registries, and was Study Director for the 2nd Australian National Blood Pressure Study. His research focus in recent years has been in the area of evidence-based management for primary and secondary prevention of cardiovascular disease.
A/Prof Reid directs the Data Management area of CCRE – Therapeutics, and is chief investigator on a number of large-scale longitudinal clinical studies and patient registries.
Professor John McNeil
Chief Investigator, CCRE - Therapeutics
Prof John McNeil is a clinical pharmacologist and epidemiologist who heads the Department of Epidemiology and Preventive Medicine at Monash University. Prof McNeil provides CCRE – Therapeutics with leadership and expertise in the application of epidemiology to the study of drug efficacy, safety and cost-effectiveness. He leads CCRE –Therapeutics’ Translational Research program and has research interests in studies of drug safety and epidemiological modelling.
Professor Andrew Tonkin
Chief Investigator, CCRE - Therapeutics
Prof Andrew Tonkin has a long-standing interest in clinical research particularly in the area of cardiology. Prof Tonkin is Director of the National Heart Foundation of Australia and Adjunct Professor in Preventive Cardiology at Monash University. Prof Tonkin provides CCRE– Therapeutics with expertise in the design and analysis of small-scale and large-scale randomized therapeutic trials.
A/Professor Flavia Cicuttini
Chief Investigator, CCRE - Therapeutics
A/Prof Cicuttini heads the Clinical Diagnostic and Chronic Diseases Unit within the Department of Epidemiology and Preventive Medicine, MonashUniversity. A/Prof Cicuttini has research interests in the development and validation of clinical outcome measures in clinical studies, especially in the development of methods for quantifying disease progression in degenerative joint disease.
Professor Paul Myles
Chief Investigator, CCRE – Therapeutics
Professor Paul Myles is the Director of Anaesthesia and Perioperative Medicine at the Alfred Hospital, and Professor of Anaesthesia at Monash University. Prof Myles is involved in a number of large multi-centre trials aiming to improve outcomes after surgery and anaesthesia. These include an investigation of nitrous oxide in anaesthesia (the ENIGMA Trial), and aspirin with or without tranexamic acid in coronary artery surgery (the ATACAS Trial).
A/Prof Andrew Forbes
Chief Investigator, CCRE – Therapeutics
A/Prof Forbes provides biostatistical expertise and professional leadership to CCRE –Therapeutics. He worked in the pharmaceutical industry in the US, before joining Monash University to head one of the largest biostatistical units in Victoria, in the Department of Epidemiology and Preventive Medicine.
A/Prof Andrew Ajani
Associate Investigator, CCRE – Therapeutics
Dr Andrew Ajani is Director of Coronary Care at the Royal Melbourne Hospital. Dr Ajani’s research interests lie in interventional cardiology and he is the convener of the Melbourne Intervention Group, who have established a large registry of coronary interventional procedures managed through the CCRE –Therapeutics Data Centre.
Professor Frank Rosenfeldt
Associate Investigator, CCRE – Therapeutics
Professor Rosenfeldt leads the Cardiac Surgical Research Unit at the Alfred and Baker Medical Research Unit. Prof Rosenfeldt has research interests in nutritional supplementation and cardiac function. His research is aimed at improving the success of procedures such as cardiac bypass and angioplasty.
A/Prof John Amerena
Associate Investigator, CCRE – Therapeutics
A/Prof Amerena is a cardiologist at Geelong Hospital and senior academic in the Department of Clinical and Biomedical Sciences at University of Melbourne. A/Prof Amerena has broad research interests in clinical cardiology, and particular interest in coronary artery disease and hypertension management.
Dr Robyn Woods
Executive Officer, ASPREE
Robyn Woods is a senior NHMRC Fellow at the Howard Florey Institute with research interests in cardiovascular physiology and the pathophysiology of cardiac natriuretic peptides.
Dr Alice Owen
Research Fellow, CCRE – Therapeutics
Alice Owen is a physiologist with research interests in cellular lipid composition and oxidative stress in cardiovascular disease, obesity and diabetes.
Dr John Varigos
Research Fellow, CCRE - Therapeutics
John Varigos is a pharmacologist with extensive experience in the management of Phase 1 to Phase 4 clinical trials. He has managed studies in a variety of indications but has a special interest in the treatment of cardiovascular disease. He has worked as Clinical Research Manager in pharmaceutical companies and Australian Director and Clinical Operations Manager for a large multinational CRO. He is a member of the International Steering Committee and Australian National Coordinator for the Oxford University based ISIS studies and the McMaster University based Cardiovascular Collaboration. These studies include ISIS 1, 2, 3 & 4, CORE, Inter-Heart, OASIS-2, OASIS-4 (CURE), ACTIVE, OASIS 5 & 6 and the OASIS ACS registry. Whilst working for BMS in Australia, he conceived and implemented the successful LIPID study.
|
